Stay updated with breaking news from Path Holdings. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HOUSTON, June 05, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ:BPTH) (“Bio-Path” or the “Company”), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a
Bio-Path Holdings, Inc. : Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. for Q1 2024. To view the full announcement, including downloadable images, bios, and...
Bio-Path Holdings, Inc. (NASDAQ:BPTH – Get Free Report) was the target of a significant drop in short interest in May. As of May 15th, there was short interest totalling 24,000 shares, a drop of 45.9% from the April 30th total of 44,400 shares. Currently, 1.5% of the company’s stock are short sold. Based on an […]
Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) – Research analysts at Roth Capital upped their Q2 2024 earnings per share estimates for shares of Bio-Path in a research note issued to investors on Wednesday, May 15th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings of ($2.06) per share for the […]
Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) – Roth Capital boosted their Q2 2024 earnings per share estimates for Bio-Path in a report released on Wednesday, May 15th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings per share of ($2.06) for the quarter, up from their previous estimate of ($4.60). […]